Physician profile
Chithranjan Nath
NPI 1053456855
$174,309.27
in general payments reported to CMS, 2019-2025
37 companies · $4,158 in 2025
The $4,158 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $41K · 2021: $47K · 2022: $8,034 · 2023: $2,929 · 2024: $4,871 · 2025: $4,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,100 · Food and Beverage: $2,681 · Consulting Fee: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,100.00 |
| Food and Beverage | $2,680.86 |
| Consulting Fee | $1,177.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $45,599.84 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $42,320.84 | 2019-2022 | |
| Novo Nordisk INC | $41,852.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $35,360.11 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $3,349.21 | 2019 | |
| Ibsa Pharma INC. | $1,058.03 | 2020-2024 | Tirosint, Licart |
| Roche Diabetes Care, INC. | $777.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $598.72 | 2019-2024 | Jardiance |
| Amneal Pharmaceuticals LLC | $419.04 | 2019-2025 | Unithroid |
| Sentynl Therapeutics, INC. | $400.00 | 2023 | |
| Lilly USA, LLC | $385.02 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $294.65 | 2019-2024 | Freestyle Libre |
| Corcept Therapeutics | $294.30 | 2019-2021 | |
| Amarin Pharma, INC. | $231.21 | 2019-2023 | |
| Radius Health, INC. | $173.31 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $139.13 | 2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $135.11 | 2023-2025 | |
| Amgen INC. | $104.47 | 2023-2024 | Tavneos, Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $96.49 | 2023-2024 | |
| Medtronic Minimed, INC. | $76.19 | 2019-2020 | |
| Janssen Biotech, INC. | $65.92 | 2024-2025 | Tremfya |
| Madrigal Pharmaceuticals | $64.46 | 2025 | Rezdiffra |
| Insulet Corporation | $58.48 | 2019-2024 | Omnipod |
| Tandem Diabetes Care, INC. | $57.09 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $56.72 | 2021-2024 | Minimed 780g |
| Dexcom, INC. | $54.98 | 2024-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $48.13 | 2020-2025 | Isturisa |
| Antares Pharma, INC. | $34.19 | 2022 | |
| Beta Bionics, INC. | $30.90 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ucb, INC. | $25.81 | 2024 | Cimzia |
| Ultragenyx Pharmaceutical INC. | $24.60 | 2024 | Crysvita |
| Sanofi Pasteur INC. | $22.84 | 2023 | |
| Mannkind Corporation | $21.85 | 2021 | |
| Horizon Therapeutics Plc | $20.87 | 2023 | Tepezza |
| Alexion Pharmaceuticals, INC. | $20.72 | 2025 | Strensiq |
| Xeris Pharmaceuticals, INC. | $19.82 | 2023 | Recorlev |
| Janssen Pharmaceuticals, INC | $17.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chithranjan Nath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.